| Autor: |
Motomura Y; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Yoshifuji K; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Tanaka K; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Sakashita C; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Umezawa Y; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Nagao T; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Nitta S; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Asahina Y; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Mori T; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Yamamoto M; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. |
| Abstrakt: |
Reactivation of hepatitis viruses during chemotherapy can be problematic in the treatment of malignant lymphomas. However, studies on reactivation of chronic hepatitis C virus (HCV) infection are limited. A 43-year-old woman presented with generalized lymphadenopathy and multiple liver tumors, and she was diagnosed with follicular lymphoma (grade 3a; clinical stage IV). Chronic HCV infection was clinically diagnosed. Immunochemotherapy (ICT), including bendamustine and obinutuzumab, was initiated with close liver function monitoring without specific treatment for hepatitis C. However, liver dysfunction worsened 17 days after ICT initiation, and ICT was interrupted. HCV-RNA and transaminase levels continued to elevate. Liver biopsy results confirmed acute exacerbation of chronic hepatitis C. Direct active antiviral (DAA) therapy was started and effective. She has maintained a sustained virologic response since DAA therapy ended. With regard to lymphoma, complete metabolic response was maintained for 4 years without additional treatment. Physicians should be aware of HCV reactivation with hepatitis flare after ICT for lymphoma and consider the indication and timing of DAA therapy for hepatitis C in this setting. |
